Discovery and development of novel salicylate synthase (MbtI) Furanic inhibitors as antitubercular agents
Articolo
Data di Pubblicazione:
2018
Citazione:
Discovery and development of novel salicylate synthase (MbtI) Furanic inhibitors as antitubercular agents / L.R. Chiarelli, M. Mori, D. Barlocco, G. Beretta, A. Gelain, E. Pini, M. Porcino, G. Mori, G. Stelitano, L. Costantino, M. Lapillo, D. Bonanni, G. Poli, T. Tuccinardi, S. Villa, F. Meneghetti. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 155(2018 Jul 15), pp. 754-763.
Abstract:
We report on the virtual screening, synthesis, and biological evaluation of new furan derivatives targeting Mycobacterium tuberculosis salicylate synthase (MbtI). A receptor-based virtual screening procedure was applied to screen the Enamine database, identifying two compounds, I and III, endowed with a good enzyme inhibitory activity. Considering the most active compound I as starting point for the development of novel MbtI inhibitors, we obtained new derivatives based on the furan scaffold. Among the SAR performed on this class, compound 1a emerged as the most potent MbtI inhibitor reported to date (Ki = 5.3 µM). Moreover, compound 1a showed a promising antimycobacterial activity (MIC99 = 156 µM), which is conceivably related to mycobactin biosynthesis inhibition.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
tuberculosis, iron, siderophores, antimycobacterial drugs, virtual screening, drug design
Elenco autori:
L.R. Chiarelli, M. Mori, D. Barlocco, G. Beretta, A. Gelain, E. Pini, M. Porcino, G. Mori, G. Stelitano, L. Costantino, M. Lapillo, D. Bonanni, G. Poli, T. Tuccinardi, S. Villa, F. Meneghetti
Link alla scheda completa: